Brought to you by 
Gilead pays $11.2bn for HCV company Pharmasset
Nov 2011
Executive Summary
In a bold move that gives it a stronger foothold in the competitive hepatitis C therapeutics market, Gilead Sciences Inc. paid $137 per share (a 96% premium), or $11.2bn, to acquire public antivirals biotech Pharmasset Inc. The purchase price is the highest ever paid for a clinical-stage biotech.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead pays $11.2bn for HCV company Pharmasset
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice